European Medicines Agency recommends approval of ravulizumab for treatment of atypical haemolytic uremic syndrome (aHUS)

The CHMP positive opinion recommends the approval of ravulizumab for the treatment of patients with a body weight ≥10kg with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.


European Medicines Agency